Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1421-1440 of 3,900 trials

Crohn's Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn's disease. The study aims to see if it helps reduce symptoms and achieve remission compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Chronic Lymphocytic Leukemia: Intermittent Ibrutinib Study

We are investigating whether taking ibrutinib intermittently can improve outcomes for people with chronic lymphocytic leukemia. This study aims to find out if this approach is effective compared to continuous treatment.

Chronic Lymphocytic LeukemiaSafety phase (I)HematologyOncology

Patellofemoral Osteoarthritis: Nasal Cartilage Implant Study

We are investigating whether a new treatment using engineered nasal cartilage can help reduce pain and improve knee function in people with osteoarthritis behind the kneecap. This study compares the new approach to standard treatments.

Knee OsteoarthritisPatellofemoral Osteoarthritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Cytomegalovirus in Pregnancy: Valacyclovir Study

We are comparing the effectiveness and safety of valacyclovir for treating primary cytomegalovirus infection in pregnant women. The study looks at how different doses may impact treatment outcomes and safety.

CMV Infection6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Advanced Solid Tumors: PM54 Treatment

We are testing a new treatment called PM54 for patients with advanced solid tumors. The goal is to evaluate its safety and how well it works compared to existing options.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Melanoma Treatment: LTX-315 and Pembrolizumab

We are studying a new treatment combination for patients with resectable stage III-IV melanoma. The goal is to see how well it shrinks tumors and affects overall health and quality of life.

Stage III Malignant Melanoma≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesDermatologyOncology

Systemic Lupus Erythematosus: SAR441344 Treatment Study

We are investigating a new medication for people with Systemic Lupus Erythematosus to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)16-20 visitsInvestigational MedicinesPartially RemoteInternal MedicineRheumatology

JJP-1212: New Immune Response Treatment

We are assessing whether JJP-1212 is safe and can effectively stimulate an immune response in humans. This study aims to understand its tolerability and potential benefits.

Linear IgA Bullous Dermatosis>2 yearsSafety phase (I)DermatologyInfectious Diseases

Colorectal Cancer: PD L 506 Oral Medication Study

We are investigating the safety of a new oral medication for patients with colorectal cancer and healthy volunteers. The study also looks at whether urine tests can help in diagnosing colorectal cancer.

Colorectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncology

C3 Glomerulopathy and ICGN: OMS906 Study

We are testing a new drug called OMS906 in patients with C3 Glomerulopathy or Idiopathic Immune Complex-Mediated Glomerulonephritis. The study aims to evaluate the safety and early effects of this treatment on kidney function.

Immune Complex Glomerulonephritis6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesNephrology

Primary IgA Nephropathy: Long-Term Study of Iptacopan

We are evaluating the long-term safety and tolerability of iptacopan in adults with primary IgA nephropathy. This study follows participants who have completed an earlier trial to see how well the treatment works over time.

IgA Nephropathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Thyroid Eye Disease: Lu AG22515 Treatment

We are investigating the effects of Lu AG22515 on eye bulging in adults with moderate-to-severe Thyroid Eye Disease. This study aims to see if it can improve symptoms related to this condition.

Thyroid Eye Disease1-2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology

Erythema Migrans: Saccharomyces boulardii Probiotic Study

We are studying the effects of a probiotic on gut health in patients taking antibiotics for erythema migrans. The goal is to see if it helps prevent diarrhea and improves gut balance during treatment.

Erythema Migrans6-12 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesGastroenterologyInfectious Diseases

Frontotemporal Dementia: DNL593 Study

We are evaluating the safety and tolerability of a new drug, DNL593, in healthy individuals and those with frontotemporal dementia. This study aims to understand how the drug works in the body and its effects over time.

Frontotemporal Dementia1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Gastrointestinal Cancers: MK-2870 Treatment Study

We are testing the safety and effectiveness of MK-2870, alone or with other cancer treatments, for people with gastrointestinal cancers. This study aims to see how well it works in reducing tumors and improving patient outcomes.

Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, and Biliary Tract Cancer6-12 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Acute Progressive Stroke: Norepinephrine Treatment

We are studying whether adding norepinephrine to standard care helps improve recovery in patients with acute progressive perforating artery stroke. The goal is to see if this combination leads to better functional outcomes and reduces complications.

Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Pancreatic Cancer: Neoadjuvant Triple Treatment Study

We are exploring a new combination of chemotherapy and immunotherapy for patients with borderline resectable pancreatic cancer. The goal is to see if this treatment improves survival and surgical outcomes.

Pancreatic CancerBorderline Resectable Pancreatic Cancer (BRPC)6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Progressive Supranuclear Palsy: 18F-PI-2620 PET Imaging Study

We are investigating a new imaging tool to help identify and understand progressive supranuclear palsy in patients. This study may improve diagnosis and treatment options for this rare neurological condition.

Parkinson's DiseaseProgressive Supranuclear Palsy>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNeurology

Vulvar Cancer: Chemoradiation Study

We are investigating if chemoradiation alone is a safe alternative to surgery for early-stage vulvar cancer patients with lymph node involvement. The study also evaluates the side effects of this treatment over time.

Vulvar Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Metastatic Colorectal and Gastroesophageal Cancer: Trifluridine/Tipiracil Study

We are studying the safety of Trifluridine/tipiracil as a new chemotherapy for patients with metastatic colorectal or gastroesophageal cancer who have a specific genetic deficiency. This trial aims to see if it can be a safer alternative to traditional treatments.

Metastatic Colon or Rectal Cancer with DPD Deficiency1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology